Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fuji
Fish and Richardson
Express Scripts
Julphar
Mallinckrodt
Federal Trade Commission
Harvard Business School
Chubb

Generated: April 24, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,342,783

« Back to Dashboard

Summary for Patent: 4,342,783
Title: Anti-glaucoma agent
Abstract:1-{4-[2-(Cyclopropylmethoxy)-ethyl]-phenoxy}-3-isopropylamino-propan-2-ol and its pharmaceutically acceptable salts, in the form of a racemate or optical isomer, are useful as topical anti-glaucoma agents.
Inventor(s): Morselli; Paolo L. (Meudon Bellevue, FR), De Santis, Jr.; Louis (Fort Worth, TX), Adamski; Robert (Fort Worth, TX)
Assignee: Synthelabo (Paris, FR)
Application Number:06/164,223
Patent Claims: 1. A method of treating glaucoma in a patient which comprises administering topically to the eye of said patient a compound of the formula: ##STR2## or a pharmaceutically acceptable salt thereof in the form of a racemate or optical isomer thereof in an amount effective to treat glaucoma by reducing interocular pressure.

2. An eye drop of claim 1 wherein said effective amount is from about 0.1 to about 2.0% of said eye drop.

3. An eye drop for the treatment of glaucoma through topical application of said eye drop to the eye of a patient suffering from glaucoma, comprising a therapeutically effective amount of a compound of the formula, ##STR3## or a pharmaceutically acceptable salt thereof, said compound being a racemate or optical isomer, said amount being effective to treat glaucoma by reducing interocular pressure, and a solvent for said compound which is suitable for topical application to the eye of a patient.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Citi
Cipla
Mallinckrodt
Express Scripts
Queensland Health
Harvard Business School
Colorcon
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.